Market Snapshot
S&P Futures
4,219
Dow Futures
33,369
Nasdaq Futures
13,343.75
Timber Pharmaceuticals, Inc.
(AMEX:TMBR)
$0.15
$0.04
37.31%
Timber Pharmaceuticals, Inc. Chart
TMBR Stock Price Today
Timber Pharmaceuticals, Inc. (TMBR) stock rallied over 37.31% intraday to trade at $0.1483 a share on AMEX. The stock opened with a gain of 23.58% at $0.11 and touched an intraday high of $0.114, rising 42.60% against the last close of $0.104. The stock went to a low of $0.103 during the session.
Stock Snapshot
$0.104
Prev. Close
6.4 Million
Market Cap
$0.103
Day Low
$0.11
Open
63.8 Million
Number of Shares
$0.114
Day High
-
P/E ratio
-0.27
EPS (TTM)
0.22
Cash Flow per Share
1.00
Free Float in %
-
Book Value
184,248,755
Volume
Timber Pharmaceuticals, Inc. Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| 2022-08-10 | $0.11 | $0.114 | $0.103 | $0.108 | 31,125,539 |
| 2022-08-09 | $0.12 | $0.12 | $0.102 | $0.104 | 48,413,600 |
| 2022-08-08 | $0.106 | $0.109 | $0.101 | $0.102 | 26,535,100 |
| 2022-08-05 | $0.1 | $0.105 | $0.099 | $0.103 | 47,775,400 |
| 2022-08-04 | $0.101 | $0.11 | $0.09 | $0.096 | 105,181,500 |
| 2022-08-03 | $0.186 | $0.19 | $0.172 | $0.173 | 1,716,500 |
| 2022-08-02 | $0.2 | $0.2 | $0.175 | $0.178 | 2,168,700 |
| 2022-08-01 | $0.214 | $0.217 | $0.185 | $0.201 | 322,300 |
| 2022-07-29 | $0.21 | $0.224 | $0.2 | $0.21 | 1,147,500 |
| 2022-07-28 | $0.23 | $0.23 | $0.214 | $0.218 | 1,072,400 |
Contact Details
Company Information
Employees-
Beta0.15
Sales or Revenue928.98 Thousands
5Y Sales Change54.7%
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryPharmaceuticals
About Company
Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. In addition, the company engages in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. It has license agreement with AFT Pharmaceuticals Limited. The company was founded in 2019 and is headquartered in Basking Ridge, New Jersey.
Frequently Asked Questions
What is the current Timber Pharmaceuticals, Inc. (TMBR) stock price?
Timber Pharmaceuticals, Inc. (AMEX: TMBR) stock price is $0.1483 as of the last check on Wednesday, August 10. During the trading session, TMBR stock reached the peak price of $0.114 while $0.103 was the lowest point it dropped to.
TMBR's industry and sector of operation?
The AMEX listed TMBR is part of Pharmaceuticals industry that operates in the broader Health Care sector. Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs.
Who are the executives of TMBR?
Mr. Joseph Lucchese
Exec. VP & CFO
Mr. Zachary Rome
Director
Mr. John Koconis M.B.A.
Chairman, CEO & Pres
Mr. Joseph Lucchese
Exec. VP, CFO, Treasurer & Sec.
What is the TMBR stock price today?
TMBR stock traded closed the last session at $0.108, which is $0.04029999999999999 or 37.31481481481481% lower than its previous close of $0.104. TMBR's current trading price is 20% lower than its 52-week high of $1.12 where as its distance from 52-week low of 0.09% is -90.36%.
How many employees does TMBR have?
Number of TMBR employees currently stands at -. TMBR operates from 110 Allen Road, Suite 401, Basking Ridge, NJ 07920, United States.
Link for TMBR official website?
Official Webiste of $TMBR is: https://www.timberpharma.com
How do I contact TMBR?
TMBR could be contacted at TMBR operates from 110 Allen Road, Suite 401, Basking Ridge, NJ 07920, United States, or at phone #973 314 9577 and can also be accessed through its website.
How many shares of TMBR are traded daily?
TMBR stock volume for the day was 184,248,755 shares while in the previous session number of TMBR shares traded was 31,125,539 . The average number of TMBR shares traded daily for last 3 months was 5.08 Million.
How much did TMBR change today?
The percentage change in TMBR stock occurred in the recent session was 37.31481481481481% while the dollar amount for the price change in TMBR stock was $0.04029999999999999.
What price range TMBR stock been trading in?
In the recent session, the day high for TMBR stock was $0.114 while the low for TMBR stock touched on the day was $0.103.
What is the market cap of TMBR currently?
The market value of TMBR currently stands at 6.4 Million with its latest stock price at $0.1483 and 63.8 Million of its shares outstanding.